The survival benefit seen with Sunitinib is a major step in the right direction when it comes to treatment of renal cell carcinoma. The median overall survival was 26.4 months for sunitinib-treated patients compared with 21.8 months for IFN-α recipients (P=0.051) and objective response rate was 47% for sunitinib compared with 12% for IFN-alpha (P < .001). This should encourage more patients and convince more treating Oncologists to consider Sutent (Sunitinib) as first line treatment of metastatic Renal Cell Cancer.
Bottom Ad
Advertisement
Subscribe
